Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML - Novartis novartis.com Submitted by novartiscom2341 on June 2, 2024 at 2:48 AM in business No comments 58